
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
2025/12/15 | 1h 7 mins.
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Ep190: Neil Kumar on Building a Rare Disease Drug Company
2025/11/20 | 1h 13 mins.
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
2025/11/12 | 1h 12 mins.
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Ep188: Art Krieg on Innate Immune System Activators for Cancer
2025/10/28 | 1h 9 mins.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

Ep187: Eric Fischer on Creating a New Class of Medicines
2025/10/14 | 1h 5 mins.
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.



The Long Run with Luke Timmerman